Diferencia entre revisiones de «Otonomy s Ear Infection Drug Succeeds In Late-stage Trial»
De Wikis2i
m |
m |
||
(No se muestra una edición intermedia de otro usuario) | |||
Línea 1: | Línea 1: | ||
− | Jan 5 (Reuters) - Drug developer Otonomy Inc said on Thursday its drug to treat acute otitis externa (AOE), an infection in the outer ear canal, [http://vtr.org.vn/3-dia-diem-khong-the-bo-qua-khi-den-tour-du-lich-dai-loan.html vtr.org.vn] met the main goal in a late-stage trial.<br><br>The drug, [http://vtr.org.vn/3-dia-diem-khong-the-bo-qua-khi-den-tour-du-lich-dai-loan.html tour đài loan | + | Jan 5 (Reuters) - Drug developer Otonomy Inc said on Thursday its drug to treat acute otitis externa (AOE), an infection in the outer ear canal, [http://vtr.org.vn/3-dia-diem-khong-the-bo-qua-khi-den-tour-du-lich-dai-loan.html vtr.org.vn] met the main goal in a late-stage trial.<br><br>The drug, [http://vtr.org.vn/3-dia-diem-khong-the-bo-qua-khi-den-tour-du-lich-dai-loan.html tour đài loan giá rẻ] Otiprio, is approved for [http://vtr.org.vn/gioi-thieu-am-thuc-dai-loan-tai-viet-nam-lan-thu-nhat.html tour đài loan giá rẻ] use in pediatric patients during tympanostomy tube placement [http://Www.Ajaxtime.com/?s=surgery surgery].<br><br>The company said it would submit a supplemental marketing approval [http://Www.ajaxtime.com/?s=application application] with the U.S. Food and Drug Administration in the first half of 2017. ([https://Www.youtube.com/results?search_query=Reporting,creativecommons Reporting] by Divya Grover in Bengaluru; Editing by Shounak Dasgupta) |
Revisión actual del 15:16 28 abr 2019
Jan 5 (Reuters) - Drug developer Otonomy Inc said on Thursday its drug to treat acute otitis externa (AOE), an infection in the outer ear canal, vtr.org.vn met the main goal in a late-stage trial.
The drug, tour đài loan giá rẻ Otiprio, is approved for tour đài loan giá rẻ use in pediatric patients during tympanostomy tube placement surgery.
The company said it would submit a supplemental marketing approval application with the U.S. Food and Drug Administration in the first half of 2017. (Reporting by Divya Grover in Bengaluru; Editing by Shounak Dasgupta)